Currently Viewing:
Supplements Current, New, and Emerging Therapies for the Prevention and Management of Migraine
Currently Reading
Migraine Overview and Summary of Current and Emerging Treatment Options
Golden L. Peters, PharmD, BCPS
Participating Faculty
Posttest

Migraine Overview and Summary of Current and Emerging Treatment Options

Golden L. Peters, PharmD, BCPS
Migraine is a leading cause of disability worldwide. Approximately 15% of Americans experience migraines. Most people who have migraines feel that people who do not have them often underestimate their condition. Migraines affect people’s quality of life and ability to participate in work, family, and social events. A new class of medication, calcitonin gene-related peptide (CGRP) antagonists, has been approved for migraine prevention in adults. The newly approved CGRP antagonists are erenumab, fremanezumab, and galcanezumab, while eptinezumab looks to 2020 for approval. Lasmiditan, ubrogepant, and rimegepant are currently emerging acute migraine therapies that may be added to the arsenal of current migraine management.
Am J Manag Care. 2019;25:-S0

Become a Member to see the rest of this article and get access to all of our articles and resources. Membership is Free!

Register
Login
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up